VJHemOnc is committed to improving our service to you

MDS 2020 | Realigning MDS treatment goals

VJHemOnc is committed to improving our service to you

Mikkael Sekeres

Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses the challenges in drug development in myelodysplastic syndromes (MDS) with respect to aligning trial endpoints for lower and higher risk patients with treatment goals meaningful to patients. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter